An adjuvant-pulsed mRNA vaccine, utilizing m5C and Ψ modifications to enhance the delivery of resiquimod (C16-R848), significantly promotes the recruitment of CD8+ T cells in prostate tumor areas, enhancing the anti-tumor efficacy of mRNA vaccine-driven immune cells (Islam et al., 2021). Here, CD8A is linked to neoplasm.